Celluvisc 0.5%

  • Name:

    Celluvisc 0.5%

  • Company:
    info
  • Active Ingredients:

    Carmellose sodium

  • Legal Category:

    Supply through pharmacy only

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/02/15

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 16/2/2015
print

Print ViewKeyword Search SmPC

Allergan Ltd

Allergan Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Acular Active Ingredients Ketorolac Trometamol
Medicine Name Alphagan Active Ingredients brimonidine tartrate
Medicine Name Betagan Active Ingredients Levobunolol hydrochloride
Medicine Name Betagan Unit Dose Active Ingredients Levobunolol hydrochloride
Medicine Name BOTOX 100 Units Active Ingredients Botulinum Toxin Type A
Medicine Name BOTOX 200 Units Active Ingredients Botulinum Toxin Type A
Medicine Name BOTOX 50 Units Active Ingredients Botulinum Toxin Type A
Medicine Name Celluvisc 0.5% Active Ingredients Carmellose sodium
Medicine Name Celluvisc 1.0% w/v Eye drops, solution Active Ingredients Carmellose sodium
Medicine Name Combigan Active Ingredients brimonidine tartrate, Timolol Maleate
Medicine Name Exocin Active Ingredients Ofloxacin
Medicine Name FML Active Ingredients Fluorometholone
Medicine Name Ganfort Active Ingredients Bimatoprost, Timolol Maleate
Medicine Name Ganfort SD Active Ingredients Bimatoprost, Timolol Maleate
Medicine Name Lacri-Lube Active Ingredients No Active Ingredients
Medicine Name Liquifilm Tears Active Ingredients Polyvinyl Alcohol
Medicine Name Lumigan 0.1mg/ml Active Ingredients Bimatoprost
Medicine Name Ozurdex Active Ingredients Dexamethasone
Medicine Name Pred Forte Active Ingredients Prednisolone Acetate
Medicine Name Pred Mild Active Ingredients Prednisolone Acetate
Medicine Name Refresh Ophthalmic Active Ingredients Polyvinyl Alcohol, Povidone
Medicine Name Relestat 0.5 mg/ml, eye drops, solution Active Ingredients Epinastine Hydrochloride
Medicine Name Vistabel Active Ingredients Botulinum Toxin Type A
1 - 0 of 23 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 16 February 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 16 February 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

To update Irish Medicines Board (IMB) name to Health Products Regulatory Authority (HPRA) in sec. 4.8 of the SPC

Updated on 12 February 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 12 February 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 4 June 2014 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Changed to update the SPC in line with the CCDS

Updated on 30 May 2014 PIL

Reasons for updating

  • Changes to therapeutic indications
  • Change to storage instructions
  • Change to side-effects
  • Change to information about driving or using machinery
  • Change to date of revision

Updated on 10 March 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Summary of Changes to Celluvisc® 0.5% Irish Summary of Product Characteristics (SPC)

 

The current Celluvisc® SPC is dated 17th December 2010

This supersedes SPC dated 10th November 2006

 

Section Number

Subject

Change

4.8

Undesirable effects

Added Text:

The frequency of adverse reactions documented during clinical trials is given.  The frequency is defined as follows: Very Common (³ 1/10); Common (³1/100, <1/10); Uncommon (³1/1,000, <1/100); Rare (³1/10,000, <1/1,000); Very Rare (<1/10,000), not known (cannot be estimated from the available data).

 

Eye disorders:

 

Common: Eye Irritation

 

The following other adverse reactions have reported since Cellufluid has been marketed:

Eye pain, vision blurred, lacrimation increased, ocular hyperaemia.

 

Deleted Text:

Temporary burning may occur.

 

 

10

Date of Revision of Text

Text added:

 

17th December 2010

 

 

 

Key:

Unchanged text appears as follows: eg sodium hydroxide

Added text appears as follows: eg Celluvisc

Deleted text appears as follows: eg Not applicable

 

Updated on 9 March 2011 PIL

Reasons for updating

  • Change to side-effects
  • Change to further information section

Updated on 21 February 2011 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 24 November 2006 PIL

Reasons for updating

  • New PIL for new product

Updated on 24 November 2006 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Supply through pharmacy only